Cargando…

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis

Objective To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sartori, Luisa Gracio Ferreira, Nunes, Bruno Monteiro, Farah, Daniela, Oliveira, Leticia Maria de, Novoa, Claudia Cristina Takano, Sartori, Marair Gracio Ferreira, Fonseca, Marcelo Cunio Machado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Revinter Publicações Ltda. 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371066/ https://www.ncbi.nlm.nih.gov/pubmed/37494577 http://dx.doi.org/10.1055/s-0043-1770093

Ejemplares similares

The Use of Three-dimensional Printer Molds for Treatment of Vaginal Agenesis
por: Takano, Claudia Cristina, et al.
Publicado: (2022)

A Decline at Inpatient Benign Hysterectomy is Perceived in Brazil: What are the Strategies to Improve Surgical Resident Training?
por: Brito, Luiz Gustavo Oliveira, et al.
Publicado: (2018)

Effects of the COVID-19 Pandemic on Gynecological Health: An Integrative Review
por: Marquini, Gisele Vissoci, et al.
Publicado: (2022)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

Athletic Incontinence: Proposal of a New Term for a New Woman
por: Araujo, Maíta Poli de, et al.
Publicado: (2017)

Early physical therapy intervention in gynaecological surgery: “Case series”
por: Monteiro Carbone, Ébe dos Santos, et al.
Publicado: (2018)

Burch Procedure: A Historical Perspective
por: Marquini, Gisele Vissoci, et al.
Publicado: (2022)

Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: A systematic review and meta-analysis
por: Yi, Wei, et al.
Publicado: (2021)

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis
por: Kennelly, Michael, et al.
Publicado: (2022)

Ultrasound Thickness of Bladder Wall in Continent and Incontinent Women and Its Correlation with Cystometry
por: Otsuki, Edney Norio, et al.
Publicado: (2014)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

Three-dimensional Printer Molds for Vaginal Agenesis: An Individualized Approach as Conservative Treatment
por: Fernandes, Marina Silva, et al.
Publicado: (2022)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
por: Shaw, Christina, et al.
Publicado: (2023)

Feminization of science: female pioneering in the healthcare area
por: Marquini, Gisele Vissoci, et al.
Publicado: (2023)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
por: Makhani, Asad, et al.
Publicado: (2020)

Effect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder
por: Han, Young Kook, et al.
Publicado: (2011)

Refractory overactive bladder: Beyond oral anticholinergic therapy
por: Glinski, Ronald W., et al.
Publicado: (2007)

Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder
por: Araklitis, George, et al.
Publicado: (2020)

A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
por: Kumar, Shailendra, et al.
Publicado: (2023)

Assessment of laparoscopic skills of Gynecology and Obstetrics residents after a training program
por: Fernandes, Carla Ferreira Kikuchi, et al.
Publicado: (2016)

Sexual function after anterior vaginal wall prolapse surgery
por: Feldner, Paulo Cezar, et al.
Publicado: (2012)

A phase II dose-ranging study of mirabegron in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2013)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
por: Allison, Sara J., et al.
Publicado: (2018)

Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)
por: Nakagomi, Hiroshi, et al.
Publicado: (2022)

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
por: Ito, Hidenori, et al.
Publicado: (2022)

Prevalence of Urinary Incontinence in CrossFit Practitioners before and during the COVID-19 Quarantine and its Relationship with Training Level: An Observational Study
por: Araujo, Maita Poli de, et al.
Publicado: (2021)

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus‐1 associated myelopathy
por: Matsuo, Tomohiro, et al.
Publicado: (2018)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
por: Johnson, Theodore M., et al.
Publicado: (2022)

Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder
por: Perk, Sinem, et al.
Publicado: (2016)

The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder
por: Gurocak, Serhat, et al.
Publicado: (2015)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1ju7kt42l6a4sb8vuln7ehj5rn